APA

Hermans M. A. W., Schrijver B., van Holten-Neelen C. C. P. A., Gerth van Wijk R., van Hagen P. M., van Daele P. L. A. & Dik W. A. (20191111). The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release. : Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Chicago

Hermans Maud A W, Schrijver Benjamin, van Holten-Neelen Conny C P A, Gerth van Wijk Roy, van Hagen P Martin, van Daele Paul L A and Dik Willem A. 20191111. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release. : Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Harvard

Hermans M. A. W., Schrijver B., van Holten-Neelen C. C. P. A., Gerth van Wijk R., van Hagen P. M., van Daele P. L. A. and Dik W. A. (20191111). The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release. : Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

MLA

Hermans Maud A W, Schrijver Benjamin, van Holten-Neelen Conny C P A, Gerth van Wijk Roy, van Hagen P Martin, van Daele Paul L A and Dik Willem A. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release. : Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 20191111.